ArticleBrain, behavior, & immunity - health2026
Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence indicates that peripheral immune changes occur in patients with isolated REM sleep behaviour disorder (iRBD) and may contribute to the conversion of this dream enactment disorder to a neurodegenerative synucleinopathy such as Parkinson's disease, dementia with Lewy bodies or multiple system atrophy. However, with only a limited number of studies conducted, the extent to which immune changes occur across diverse iRBD cohorts remains to be determined. Objectives: We therefore aimed to assess peripheral immune changes in an Australian cohort of iRBD patients (n = 65) compared to controls (n = 35). Methods: A 9-plex cytokine assay was used to measure serum levels of IFNγ, IL-10, IL-12, IL-17A, IL-1β, IL-2, IL-4, IL-6 and TFNα. Flow cytometry was used to assess T cell populations in the same participants. Results: Exploratory analyses revealed lower levels of the T cell regulating cytokine interleukin 2 (IL-2) in participants with iRBD, along with lower frequencies of CD4 T cells positive for IL-2, IL-4 and IL-10. Conclusions: These results add to evidence of immune alterations in iRBD and suggest that dysregulation of cytokines with anti-inflammatory properties may be an early event that could associate with subsequent development of a neurodegenerative synucleinopathy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.